APA (7th ed.) Citation

AT, R., DW, G., KM, H., PG, L., & DE, H. (2023). Overview of the regulatory approval of tecovirimat intravenous formulation for treatment of smallpox: Potential impact on smallpox outbreak response capabilities, and future tecovirimat development potential. Expert review of anti-infective therapy, 21(3), 235. https://doi.org/10.1080/14787210.2023.2170350

Chicago Style (17th ed.) Citation

AT, Russo, Grosenbach DW, Honeychurch KM, Long PG, and Hruby DE. "Overview of the Regulatory Approval of Tecovirimat Intravenous Formulation for Treatment of Smallpox: Potential Impact on Smallpox Outbreak Response Capabilities, and Future Tecovirimat Development Potential." Expert Review of Anti-infective Therapy 21, no. 3 (2023): 235. https://doi.org/10.1080/14787210.2023.2170350.

MLA (9th ed.) Citation

AT, Russo, et al. "Overview of the Regulatory Approval of Tecovirimat Intravenous Formulation for Treatment of Smallpox: Potential Impact on Smallpox Outbreak Response Capabilities, and Future Tecovirimat Development Potential." Expert Review of Anti-infective Therapy, vol. 21, no. 3, 2023, p. 235, https://doi.org/10.1080/14787210.2023.2170350.